Ep 35 TRAILER: End of Life care

10/14/24 • 1 min

Melanoma Matters

A trailer on our conversation about end of life care in melanoma

A trailer on our conversation about end of life care in melanoma

Previous Episode

Ep 35: End of Life care

Summary

Our hosts guilty pleasures - junk food and South Park! Endless laughs about South Park...

In this episode of Melanoma Matters, Sapna Patel and James Larkin discuss the complexities of end-of-life care in patients with melanoma. They explore the importance of early conversations about treatment options, the role of palliative care, and the emotional and cultural aspects of dying. The discussion emphasizes the need for clear communication with patients regarding their treatment goals and the transition to palliative care as the disease progresses.

Keywords

melanoma, end of life, palliative care, treatment decisions, steroid use, goals of care, symptom management, cultural perspectives

Takeaways

End-of-life conversations should start early in treatment.
Palliative care teams can provide essential support.
Patients often feel better initially on targeted therapies.
Cultural perspectives influence how patients view death.
It's crucial to listen to patients' feelings about their treatment.
Transitioning to palliative care requires careful planning.
Symptom management is a key focus in end-of-life care.
Communication with families is vital for understanding wishes.
Patients may resist discussions about end-of-life care.
Healthcare providers must be comfortable discussing death.

Titles

The Importance of Early Goals of Care

Navigating End of Life in Melanoma Care

Sound Bites

"What's the minimal amount of therapy?"

"Transitioning to a different phase of treatment."

"It's important to have those conversations early."

Chapters

00:00 Introduction and Guilty Pleasures

05:21 Transitioning to Non-Curative Treatment

09:39 Early Goals of Care Discussions

11:55 The Limitations of BRAF Targeted Therapy

14:07 Connecting Patients to Palliative Care

15:59 Options for End-of-Life Care

16:29 Challenges of Delivering Nursing Care at Home

17:32 Limitations of Hospice Care

19:50 The Role of Targeted Therapies in Palliative Care

24:06 Managing Symptoms with Steroids

33:20 Medical Assistance in Dying

Next Episode

Ep 36: Indirect comparison CM 067 v RELA 047

Summary

James is back from holiday and tells us the peak, pit, and bud of his time away. (Spoiler: the pit was NOT a broken tooth!) He also shares a tip for time management and email hygiene on holiday. Sapna makes an unfortunate wardrobe choice (noisy, not visual).

In this episode of Melanoma Matters, hosts Sapna and James delve into the complexities of indirect treatment comparisons in melanoma therapy. They discuss a recently published paper comparing nivolumab plus relatlimab versus nivolumab plus ipilimumab, exploring the statistical methodologies, clinical implications, and biological plausibility of the findings. The conversation highlights the importance of understanding treatment options, patient selection, and future directions in melanoma treatment strategies.

Keywords

melanoma, indirect treatment comparison, nivolumab, relatlimab, ipilimumab, clinical trials, biomarkers, treatment strategies, patient care, oncology

Takeaways

Indirect treatment comparisons are a valid methodology.

Statistical methodologies can be complex but are essential for comparisons.

The efficacy of treatments can vary based on patient characteristics.

Biological plausibility is crucial in interpreting treatment outcomes.

LDH levels can be significant biomarkers in treatment decisions.

Ipilimumab plus nivolumab is considered a potent treatment regimen.

Patient experience and clinical data inform treatment choices.

Future strategies may involve combining therapies for better outcomes.

Understanding the nuances of clinical trials is vital for practitioners.